Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Companian Diagnostic Technologies Market by THERAPEUTICS (Oncology diseases): Global Opportunity Analysis and Industry Forecast, 2023-2032

A00052

Pages: NA

Charts: NA

Tables: NA

Companion diagnostic is an in-vitro diagnostic process that provides information about therapeutic response of patient for a specific treatment. This tool improves the therapeutic efficiency and decreases healthcare cost. According to PricewaterhouseCooper (PwC) report, the number of pharmaceutical and diagnostic companies has increased from 19 in 2009 to 44 in 2010. Companion diagnostic is a segment of personalized medicine that includes drug-testing, therapies, clinical trials and research. Increase in demand for targeted therapies is attracting pharmaceutical companies to develop low cost and highly efficient drugs. Commercialization of Pfizer’s targeted lung cancer therapeutics and Roche’s personalized therapies indicated the increased value for companion diagnostic market. Companion diagnostic market growth is hindered because of latency in approval of technologies. Companies are taking longer time for approval of drugs and therapies. For Example, Abbott, Pfizer, Bayer, Life Technologies and GSK are facing challenges to receive approval for commercialization from the FDA.

The demand for increased awareness in personalized medicines and cost effective diagnosis is changing the landscape of pharmaceutical companies. Companies engaged in diagnostic research are facing challenges in terms of adoption of novel therapies in healthcare market, and competition for gaining competitive advantages to position their products. This report focuses on recent development happened in companion diagnostic market and its comparative analysis, thereby providing intelligence to companies involved in personalized medicines.

The key players included are Assurerx Health, Asuragen Inc., Beckman Coulter Inc., Bg Medicine Inc., Biocrates Life Sciences Ag, Cardiodx, Celera, Dako (Agilent Technologies), Diagnocure Inc., Epigenomics Ag, Foundation Medicine Inc., Genelex Corp., Genmark Diagnostics.

KEY BENEFITS

  • In depth intelligence of top factors such as drivers, restraints and opportunities influencing companion diagnostic market growth.
  • Value chain analysis provides flow of therapies and monitoring in various chains of diagnostic segments These segments are analyzed and presented in detail in the report
  • Therapeutics segment of companion diagnostic market is thoroughly explained with GE9 Cell matrix
  • SWOT analysis and strategic developments are included in the report for Key market players to get better understanding of potential opportunities and challenges for companies.
  • The report provides intelligence on diagnostic technology adoption according to geographies, that assists research institutes to take developmental decision

 Key Market Segments

  • By THERAPEUTICS
    • Oncology diseases
      • Breast Cancer
      • Lung Cancer
      • Colorectal Cancer
      • Gastric Cancer
      • Others
  • By GEOGRAPHY
    • North America
    • Europe
    • Asia-Pacific
    • ROW

 
Key Market Players

  • Pharmaceutical companies
  • Academic institutes
  • Government regulatory authorities
  • Research companies

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET, BY THERAPEUTICS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapeutics

    • 4.2. Oncology Diseases

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Breast Cancer

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Lung Cancer

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Colorectal Cancer

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Gastric Cancer

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Others

        • 4.2.4.1. Market Size and Forecast

  • CHAPTER 5: COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET, BY REGION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Region

    • 5.2. North America

      • 5.2.1. Key Market Trends and Opportunities

      • 5.2.2. Market Size and Forecast, By Therapeutics

      • 5.2.3. Market Size and Forecast, By Country

      • 5.2.4. U.S. Companian Diagnostic Technologies Market

        • 5.2.4.1. Market Size and Forecast, By Therapeutics

      • 5.2.5. Canada Companian Diagnostic Technologies Market

        • 5.2.5.1. Market Size and Forecast, By Therapeutics

      • 5.2.6. Mexico Companian Diagnostic Technologies Market

        • 5.2.6.1. Market Size and Forecast, By Therapeutics

    • 5.3. Europe

      • 5.3.1. Key Market Trends and Opportunities

      • 5.3.2. Market Size and Forecast, By Therapeutics

      • 5.3.3. Market Size and Forecast, By Country

      • 5.3.4. France Companian Diagnostic Technologies Market

        • 5.3.4.1. Market Size and Forecast, By Therapeutics

      • 5.3.5. Germany Companian Diagnostic Technologies Market

        • 5.3.5.1. Market Size and Forecast, By Therapeutics

      • 5.3.6. Italy Companian Diagnostic Technologies Market

        • 5.3.6.1. Market Size and Forecast, By Therapeutics

      • 5.3.7. Spain Companian Diagnostic Technologies Market

        • 5.3.7.1. Market Size and Forecast, By Therapeutics

      • 5.3.8. UK Companian Diagnostic Technologies Market

        • 5.3.8.1. Market Size and Forecast, By Therapeutics

      • 5.3.9. Russia Companian Diagnostic Technologies Market

        • 5.3.9.1. Market Size and Forecast, By Therapeutics

      • 5.3.10. Rest Of Europe Companian Diagnostic Technologies Market

        • 5.3.10.1. Market Size and Forecast, By Therapeutics

    • 5.4. Asia-Pacific

      • 5.4.1. Key Market Trends and Opportunities

      • 5.4.2. Market Size and Forecast, By Therapeutics

      • 5.4.3. Market Size and Forecast, By Country

      • 5.4.4. China Companian Diagnostic Technologies Market

        • 5.4.4.1. Market Size and Forecast, By Therapeutics

      • 5.4.5. Japan Companian Diagnostic Technologies Market

        • 5.4.5.1. Market Size and Forecast, By Therapeutics

      • 5.4.6. India Companian Diagnostic Technologies Market

        • 5.4.6.1. Market Size and Forecast, By Therapeutics

      • 5.4.7. South Korea Companian Diagnostic Technologies Market

        • 5.4.7.1. Market Size and Forecast, By Therapeutics

      • 5.4.8. Australia Companian Diagnostic Technologies Market

        • 5.4.8.1. Market Size and Forecast, By Therapeutics

      • 5.4.9. Thailand Companian Diagnostic Technologies Market

        • 5.4.9.1. Market Size and Forecast, By Therapeutics

      • 5.4.10. Malaysia Companian Diagnostic Technologies Market

        • 5.4.10.1. Market Size and Forecast, By Therapeutics

      • 5.4.11. Indonesia Companian Diagnostic Technologies Market

        • 5.4.11.1. Market Size and Forecast, By Therapeutics

      • 5.4.12. Rest of Asia Pacific Companian Diagnostic Technologies Market

        • 5.4.12.1. Market Size and Forecast, By Therapeutics

    • 5.5. LAMEA

      • 5.5.1. Key Market Trends and Opportunities

      • 5.5.2. Market Size and Forecast, By Therapeutics

      • 5.5.3. Market Size and Forecast, By Country

      • 5.5.4. Brazil Companian Diagnostic Technologies Market

        • 5.5.4.1. Market Size and Forecast, By Therapeutics

      • 5.5.5. South Africa Companian Diagnostic Technologies Market

        • 5.5.5.1. Market Size and Forecast, By Therapeutics

      • 5.5.6. Saudi Arabia Companian Diagnostic Technologies Market

        • 5.5.6.1. Market Size and Forecast, By Therapeutics

      • 5.5.7. UAE Companian Diagnostic Technologies Market

        • 5.5.7.1. Market Size and Forecast, By Therapeutics

      • 5.5.8. Argentina Companian Diagnostic Technologies Market

        • 5.5.8.1. Market Size and Forecast, By Therapeutics

      • 5.5.9. Rest of LAMEA Companian Diagnostic Technologies Market

        • 5.5.9.1. Market Size and Forecast, By Therapeutics

  • CHAPTER 6: COMPETITIVE LANDSCAPE

    • 6.1. Introduction

    • 6.2. Top Winning Strategies

    • 6.3. Product Mapping Of Top 10 Player

    • 6.4. Competitive Dashboard

    • 6.5. Competitive Heatmap

    • 6.6. Top Player Positioning, 2024

  • CHAPTER 7: COMPANY PROFILES

    • 7.1. Pharmaceutical Companies

      • 7.1.1. Company Overview

      • 7.1.2. Key Executives

      • 7.1.3. Company Snapshot

      • 7.1.4. Operating Business Segments

      • 7.1.5. Product Portfolio

      • 7.1.6. Business Performance

      • 7.1.7. Key Strategic Moves and Developments

    • 7.2. Government Regulatory Authorities

      • 7.2.1. Company Overview

      • 7.2.2. Key Executives

      • 7.2.3. Company Snapshot

      • 7.2.4. Operating Business Segments

      • 7.2.5. Product Portfolio

      • 7.2.6. Business Performance

      • 7.2.7. Key Strategic Moves and Developments

    • 7.3. Research Companies

      • 7.3.1. Company Overview

      • 7.3.2. Key Executives

      • 7.3.3. Company Snapshot

      • 7.3.4. Operating Business Segments

      • 7.3.5. Product Portfolio

      • 7.3.6. Business Performance

      • 7.3.7. Key Strategic Moves and Developments

    • 7.4. Academic Institutes

      • 7.4.1. Company Overview

      • 7.4.2. Key Executives

      • 7.4.3. Company Snapshot

      • 7.4.4. Operating Business Segments

      • 7.4.5. Product Portfolio

      • 7.4.6. Business Performance

      • 7.4.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET FOR ONCOLOGY DISEASES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. NORTH AMERICA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. NORTH AMERICA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 6. U.S. COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 7. CANADA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 8. MEXICO COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 9. EUROPE COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. EUROPE COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 11. FRANCE COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 12. GERMANY COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 13. ITALY COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 14. SPAIN COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 15. UK COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 16. RUSSIA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 17. REST OF EUROPE COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 18. ASIA-PACIFIC COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 19. ASIA-PACIFIC COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 20. CHINA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 21. JAPAN COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 22. INDIA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 23. SOUTH KOREA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 24. AUSTRALIA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 25. THAILAND COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 26. MALAYSIA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 27. INDONESIA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 28. REST OF ASIA PACIFIC COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 29. LAMEA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 30. LAMEA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 31. BRAZIL COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 32. SOUTH AFRICA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 33. SAUDI ARABIA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 34. UAE COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 35. ARGENTINA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 36. REST OF LAMEA COMPANIAN DIAGNOSTIC TECHNOLOGIES, BY THERAPEUTICS, 2025-2033 ($MILLION)
  • TABLE 37. PHARMACEUTICAL COMPANIES: KEY EXECUTIVES
  • TABLE 38. PHARMACEUTICAL COMPANIES: COMPANY SNAPSHOT
  • TABLE 39. PHARMACEUTICAL COMPANIES: OPERATING SEGMENTS
  • TABLE 40. PHARMACEUTICAL COMPANIES: PRODUCT PORTFOLIO
  • TABLE 41. PHARMACEUTICAL COMPANIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 42. GOVERNMENT REGULATORY AUTHORITIES: KEY EXECUTIVES
  • TABLE 43. GOVERNMENT REGULATORY AUTHORITIES: COMPANY SNAPSHOT
  • TABLE 44. GOVERNMENT REGULATORY AUTHORITIES: OPERATING SEGMENTS
  • TABLE 45. GOVERNMENT REGULATORY AUTHORITIES: PRODUCT PORTFOLIO
  • TABLE 46. GOVERNMENT REGULATORY AUTHORITIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 47. RESEARCH COMPANIES: KEY EXECUTIVES
  • TABLE 48. RESEARCH COMPANIES: COMPANY SNAPSHOT
  • TABLE 49. RESEARCH COMPANIES: OPERATING SEGMENTS
  • TABLE 50. RESEARCH COMPANIES: PRODUCT PORTFOLIO
  • TABLE 51. RESEARCH COMPANIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 52. ACADEMIC INSTITUTES: KEY EXECUTIVES
  • TABLE 53. ACADEMIC INSTITUTES: COMPANY SNAPSHOT
  • TABLE 54. ACADEMIC INSTITUTES: OPERATING SEGMENTS
  • TABLE 55. ACADEMIC INSTITUTES: PRODUCT PORTFOLIO
  • TABLE 56. ACADEMIC INSTITUTES: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET
  • FIGURE 3. SEGMENTATION COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCOMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET
  • FIGURE 11. COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET SEGMENTATION, BY BY THERAPEUTICS
  • FIGURE 12. COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 17. COMPETITIVE DASHBOARD
  • FIGURE 18. COMPETITIVE HEATMAP: COMPANIAN DIAGNOSTIC TECHNOLOGIES MARKET
  • FIGURE 19. TOP PLAYER POSITIONING, 2024
  • FIGURE 20. PHARMACEUTICAL COMPANIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 21. PHARMACEUTICAL COMPANIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 22. PHARMACEUTICAL COMPANIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 23. GOVERNMENT REGULATORY AUTHORITIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 24. GOVERNMENT REGULATORY AUTHORITIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 25. GOVERNMENT REGULATORY AUTHORITIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 26. RESEARCH COMPANIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 27. RESEARCH COMPANIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 28. RESEARCH COMPANIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 29. ACADEMIC INSTITUTES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. ACADEMIC INSTITUTES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. ACADEMIC INSTITUTES: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Companian Diagnostic Technologies Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved